Procter & Gamble (NYSE: PG) announced its intention to acquire premium supplement manufacturer Thorne for $3.8 billion, a strategic move that underscores the consumer giant's push into high-growth wellness categories. The transaction, disclosed early Tuesday, values Thorne at approximately 5.8 times its projected 2026 sales of $650 million, according to Reuters.
CEO Shailesh Jejurikar confirmed the deal in an interview with CNBC, noting that the acquisition is expected to close later in 2026, subject to regulatory approvals. The purchase price represents a significant premium, reflecting the robust growth trajectory Thorne has demonstrated in recent years. Thorne's sales are forecast to climb from $290 million in 2023 to roughly $650 million by 2026, implying a compound annual growth rate of nearly 31%.
This acquisition comes at a time when P&G's core growth has moderated. The company reported net sales growth of just 3% in fiscal 2026, with organic sales up only 1%. Management projects organic sales growth of 1% to 3% for fiscal 2027. In contrast, Thorne's rapid expansion offers a potential catalyst to rejuvenate P&G's health care segment, which saw organic sales decline 1% in the fourth quarter, dragged down by softness in oral care.
The valuation multiple highlights the premium P&G is willing to pay for growth. Thorne's projected sales contribution to P&G's total revenue is modest, estimated at just 0.75% of the company's fiscal 2026 group sales of $87.03 billion. However, within P&G's Health Care division, Thorne would represent approximately 5.2% of the segment's $12.46 billion in sales, making it a meaningful addition to that portfolio.
Financially, P&G is well-positioned to absorb the acquisition. The company generated $19.56 billion in operating cash flow during fiscal 2026, and its market capitalization stands at $341.93 billion. The $3.8 billion deal price represents only 19.4% of operating cash flow and 1.1% of market cap, underscoring the relative size of the transaction.
P&G's health care chief, Paul Gama, emphasized that the combination could help broaden Thorne's market reach while maintaining its premium positioning. Jejurikar described the valuation as "in line with the industry benchmarks we've seen," though the company did not disclose specific margin or synergy targets. The deal follows Unilever's acquisition of supplements brand Grüns earlier this year, highlighting intensifying competition in the wellness space.
Investor reaction was mildly positive, with P&G shares rising 1.29% to $146.84 in early trading, though this lagged the broader market's gain of 1.63% as measured by the SPDR S&P 500 ETF (NYSEARCA: SPY). The modest move suggests investors are cautiously optimistic but recognize the limited near-term impact on P&G's overall financials.
The strategic rationale rests on Thorne's growth potential. With its practitioner-focused channel and product lines including creatine, prenatal vitamins, and hormone supplements, Thorne complements P&G's existing brands such as New Chapter, Metamucil, and Align. The acquisition aims to capitalize on rising consumer demand for premium health products, a trend that eMarketer analyst Rachel Wolff says is "a clear indicator of where consumer demand is currently strongest."
However, risks remain. Integration challenges could dilute Thorne's premium brand equity, and increased competition in the supplements market may slow its growth. Regulatory hurdles and unspecified financing details also pose uncertainties. The deal's success will depend on P&G's ability to scale Thorne while preserving the trust of healthcare practitioners who recommend its products.
